Influence of CYP2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis
This study aimed to investigate the influence of CYP2C9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite, E-3174, through a systematic review and meta-analysis. Eight studies published before March 2021 were included in this study. We used PubMed, the Cochrane Libr...
Gespeichert in:
| Veröffentlicht in: | Journal of personalized medicine 2021-06, Vol.11 (7), p.617 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 617 |
| container_title | Journal of personalized medicine |
| container_volume | 11 |
| creator | Park, Yoon-A Song, Yu-bin Yee, Jeong Yoon, Ha-Young Gwak, Hye-Sun |
| description | This study aimed to investigate the influence of CYP2C9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite, E-3174, through a systematic review and meta-analysis. Eight studies published before March 2021 were included in this study. We used PubMed, the Cochrane Library, EMBASE, and Web of Science, based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The data analysis was conducted through Review Manager (RevMan), version 5.3, and R software. We found that healthy volunteers with CYP2C9*2 or *3 carriers had higher area under the curve (AUC0-∞) of losartan (mean difference (MD) 0.17 μg·h/mL; 95% confidence intervals (CI): 0.04, 0.29) and lower AUC0-∞ of E-3174 (MD −0.35 μg·h/mL; 95% CI: −0.62, −0.08) than those with CYP2C9*1/*1. Subjects with CYP2C9*2 or *3 carriers showed lower maximum concentration (Cmax) of E-3174 than those with CYP2C9*1/*1 (MD −0.13 μg/mL; 95% CI: −0.17, −0.09). For half-life, subjects with CYP2C9*2 or *3 carriers had longer half-lives of losartan and E-3174 than those with CYP2C9*1/*1 (MD 0.47 h; 95% CI: 0.32, 0.61 and MD 0.68 h; 95% CI: 0.44, 0.92, respectively). This meta-analysis suggests that the pharmacokinetics of losartan and E-3174 are associated with the CYP2C9 polymorphisms |
| doi_str_mv | 10.3390/jpm11070617 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8303964</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2554584946</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-54de1fff3767ed90d09125972072439eda0053c10570a9720336172610d1bcb33</originalsourceid><addsrcrecordid>eNpdkU1r3DAQhkVpSEKaU_6AoJdAcatv2zkUliVNF7Zk6cehJ6GVx11tbWkjyVv2h-T_xk5CSavLCOmZd-adQeiCkvec1-TDdtdTSkqiaPkKnTJSykIIpl6_uJ-g85S2ZDyVZEyRY3TCBaOESHWK7he-7QbwFnBo8fznis1rfAMesrN4FbpDH-Ju41KfcPA4bwCvNib2xobf7hFKU94yJBOz8dj4Bi9ywjOb3R7wF8hmHTqXAV8XnJbiCs_wt0PK0JupwFfYO_jzmDWhxcyb7pBceoOOWtMlOH-OZ-jHp-vv88_F8vZmMZ8tC8srlQspGqBt2_JSldDUpCE1ZbIuR-tM8BoaM5rklhJZEjM9cz7OiSlKGrq2a87P0Mcn3d2w7qGx4HM0nd5F15t40ME4_e-Pdxv9K-x1xQmvlRgFLp8FYrgbIGXdu2Sh64yHMCTNpKjE1AQd0bf_odswxNHwREkhK1ELNVLvnigbQ0oR2r_NUKKnjesXG-cPOLqbew</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2554584946</pqid></control><display><type>article</type><title>Influence of CYP2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><source>EZB*</source><source>PubMed Central Open Access</source><creator>Park, Yoon-A ; Song, Yu-bin ; Yee, Jeong ; Yoon, Ha-Young ; Gwak, Hye-Sun</creator><creatorcontrib>Park, Yoon-A ; Song, Yu-bin ; Yee, Jeong ; Yoon, Ha-Young ; Gwak, Hye-Sun</creatorcontrib><description>This study aimed to investigate the influence of CYP2C9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite, E-3174, through a systematic review and meta-analysis. Eight studies published before March 2021 were included in this study. We used PubMed, the Cochrane Library, EMBASE, and Web of Science, based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The data analysis was conducted through Review Manager (RevMan), version 5.3, and R software. We found that healthy volunteers with CYP2C9*2 or *3 carriers had higher area under the curve (AUC0-∞) of losartan (mean difference (MD) 0.17 μg·h/mL; 95% confidence intervals (CI): 0.04, 0.29) and lower AUC0-∞ of E-3174 (MD −0.35 μg·h/mL; 95% CI: −0.62, −0.08) than those with CYP2C9*1/*1. Subjects with CYP2C9*2 or *3 carriers showed lower maximum concentration (Cmax) of E-3174 than those with CYP2C9*1/*1 (MD −0.13 μg/mL; 95% CI: −0.17, −0.09). For half-life, subjects with CYP2C9*2 or *3 carriers had longer half-lives of losartan and E-3174 than those with CYP2C9*1/*1 (MD 0.47 h; 95% CI: 0.32, 0.61 and MD 0.68 h; 95% CI: 0.44, 0.92, respectively). This meta-analysis suggests that the pharmacokinetics of losartan and E-3174 are associated with the CYP2C9 polymorphisms</description><identifier>ISSN: 2075-4426</identifier><identifier>EISSN: 2075-4426</identifier><identifier>DOI: 10.3390/jpm11070617</identifier><identifier>PMID: 34210056</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Cytochrome ; Ethnicity ; Gene polymorphism ; Meta-analysis ; Metabolism ; Metabolites ; Oral administration ; Pharmacokinetics ; Precision medicine ; Review ; Reviews ; Sensitivity analysis ; Systematic review</subject><ispartof>Journal of personalized medicine, 2021-06, Vol.11 (7), p.617</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-54de1fff3767ed90d09125972072439eda0053c10570a9720336172610d1bcb33</citedby><cites>FETCH-LOGICAL-c386t-54de1fff3767ed90d09125972072439eda0053c10570a9720336172610d1bcb33</cites><orcidid>0000-0003-0278-2563 ; 0000-0002-9162-2555</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303964/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303964/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Park, Yoon-A</creatorcontrib><creatorcontrib>Song, Yu-bin</creatorcontrib><creatorcontrib>Yee, Jeong</creatorcontrib><creatorcontrib>Yoon, Ha-Young</creatorcontrib><creatorcontrib>Gwak, Hye-Sun</creatorcontrib><title>Influence of CYP2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis</title><title>Journal of personalized medicine</title><description>This study aimed to investigate the influence of CYP2C9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite, E-3174, through a systematic review and meta-analysis. Eight studies published before March 2021 were included in this study. We used PubMed, the Cochrane Library, EMBASE, and Web of Science, based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The data analysis was conducted through Review Manager (RevMan), version 5.3, and R software. We found that healthy volunteers with CYP2C9*2 or *3 carriers had higher area under the curve (AUC0-∞) of losartan (mean difference (MD) 0.17 μg·h/mL; 95% confidence intervals (CI): 0.04, 0.29) and lower AUC0-∞ of E-3174 (MD −0.35 μg·h/mL; 95% CI: −0.62, −0.08) than those with CYP2C9*1/*1. Subjects with CYP2C9*2 or *3 carriers showed lower maximum concentration (Cmax) of E-3174 than those with CYP2C9*1/*1 (MD −0.13 μg/mL; 95% CI: −0.17, −0.09). For half-life, subjects with CYP2C9*2 or *3 carriers had longer half-lives of losartan and E-3174 than those with CYP2C9*1/*1 (MD 0.47 h; 95% CI: 0.32, 0.61 and MD 0.68 h; 95% CI: 0.44, 0.92, respectively). This meta-analysis suggests that the pharmacokinetics of losartan and E-3174 are associated with the CYP2C9 polymorphisms</description><subject>Cytochrome</subject><subject>Ethnicity</subject><subject>Gene polymorphism</subject><subject>Meta-analysis</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Oral administration</subject><subject>Pharmacokinetics</subject><subject>Precision medicine</subject><subject>Review</subject><subject>Reviews</subject><subject>Sensitivity analysis</subject><subject>Systematic review</subject><issn>2075-4426</issn><issn>2075-4426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkU1r3DAQhkVpSEKaU_6AoJdAcatv2zkUliVNF7Zk6cehJ6GVx11tbWkjyVv2h-T_xk5CSavLCOmZd-adQeiCkvec1-TDdtdTSkqiaPkKnTJSykIIpl6_uJ-g85S2ZDyVZEyRY3TCBaOESHWK7he-7QbwFnBo8fznis1rfAMesrN4FbpDH-Ju41KfcPA4bwCvNib2xobf7hFKU94yJBOz8dj4Bi9ywjOb3R7wF8hmHTqXAV8XnJbiCs_wt0PK0JupwFfYO_jzmDWhxcyb7pBceoOOWtMlOH-OZ-jHp-vv88_F8vZmMZ8tC8srlQspGqBt2_JSldDUpCE1ZbIuR-tM8BoaM5rklhJZEjM9cz7OiSlKGrq2a87P0Mcn3d2w7qGx4HM0nd5F15t40ME4_e-Pdxv9K-x1xQmvlRgFLp8FYrgbIGXdu2Sh64yHMCTNpKjE1AQd0bf_odswxNHwREkhK1ELNVLvnigbQ0oR2r_NUKKnjesXG-cPOLqbew</recordid><startdate>20210629</startdate><enddate>20210629</enddate><creator>Park, Yoon-A</creator><creator>Song, Yu-bin</creator><creator>Yee, Jeong</creator><creator>Yoon, Ha-Young</creator><creator>Gwak, Hye-Sun</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0278-2563</orcidid><orcidid>https://orcid.org/0000-0002-9162-2555</orcidid></search><sort><creationdate>20210629</creationdate><title>Influence of CYP2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis</title><author>Park, Yoon-A ; Song, Yu-bin ; Yee, Jeong ; Yoon, Ha-Young ; Gwak, Hye-Sun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-54de1fff3767ed90d09125972072439eda0053c10570a9720336172610d1bcb33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cytochrome</topic><topic>Ethnicity</topic><topic>Gene polymorphism</topic><topic>Meta-analysis</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Oral administration</topic><topic>Pharmacokinetics</topic><topic>Precision medicine</topic><topic>Review</topic><topic>Reviews</topic><topic>Sensitivity analysis</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Yoon-A</creatorcontrib><creatorcontrib>Song, Yu-bin</creatorcontrib><creatorcontrib>Yee, Jeong</creatorcontrib><creatorcontrib>Yoon, Ha-Young</creatorcontrib><creatorcontrib>Gwak, Hye-Sun</creatorcontrib><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of personalized medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Yoon-A</au><au>Song, Yu-bin</au><au>Yee, Jeong</au><au>Yoon, Ha-Young</au><au>Gwak, Hye-Sun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of CYP2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis</atitle><jtitle>Journal of personalized medicine</jtitle><date>2021-06-29</date><risdate>2021</risdate><volume>11</volume><issue>7</issue><spage>617</spage><pages>617-</pages><issn>2075-4426</issn><eissn>2075-4426</eissn><abstract>This study aimed to investigate the influence of CYP2C9 genetic polymorphisms on the pharmacokinetics of losartan and its active metabolite, E-3174, through a systematic review and meta-analysis. Eight studies published before March 2021 were included in this study. We used PubMed, the Cochrane Library, EMBASE, and Web of Science, based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The data analysis was conducted through Review Manager (RevMan), version 5.3, and R software. We found that healthy volunteers with CYP2C9*2 or *3 carriers had higher area under the curve (AUC0-∞) of losartan (mean difference (MD) 0.17 μg·h/mL; 95% confidence intervals (CI): 0.04, 0.29) and lower AUC0-∞ of E-3174 (MD −0.35 μg·h/mL; 95% CI: −0.62, −0.08) than those with CYP2C9*1/*1. Subjects with CYP2C9*2 or *3 carriers showed lower maximum concentration (Cmax) of E-3174 than those with CYP2C9*1/*1 (MD −0.13 μg/mL; 95% CI: −0.17, −0.09). For half-life, subjects with CYP2C9*2 or *3 carriers had longer half-lives of losartan and E-3174 than those with CYP2C9*1/*1 (MD 0.47 h; 95% CI: 0.32, 0.61 and MD 0.68 h; 95% CI: 0.44, 0.92, respectively). This meta-analysis suggests that the pharmacokinetics of losartan and E-3174 are associated with the CYP2C9 polymorphisms</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34210056</pmid><doi>10.3390/jpm11070617</doi><orcidid>https://orcid.org/0000-0003-0278-2563</orcidid><orcidid>https://orcid.org/0000-0002-9162-2555</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2075-4426 |
| ispartof | Journal of personalized medicine, 2021-06, Vol.11 (7), p.617 |
| issn | 2075-4426 2075-4426 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8303964 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central; EZB*; PubMed Central Open Access |
| subjects | Cytochrome Ethnicity Gene polymorphism Meta-analysis Metabolism Metabolites Oral administration Pharmacokinetics Precision medicine Review Reviews Sensitivity analysis Systematic review |
| title | Influence of CYP2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T05%3A54%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20CYP2C9%20Genetic%20Polymorphisms%20on%20the%20Pharmacokinetics%20of%20Losartan%20and%20Its%20Active%20Metabolite%20E-3174:%20A%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=Journal%20of%20personalized%20medicine&rft.au=Park,%20Yoon-A&rft.date=2021-06-29&rft.volume=11&rft.issue=7&rft.spage=617&rft.pages=617-&rft.issn=2075-4426&rft.eissn=2075-4426&rft_id=info:doi/10.3390/jpm11070617&rft_dat=%3Cproquest_pubme%3E2554584946%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2554584946&rft_id=info:pmid/34210056&rfr_iscdi=true |